The proposed CMS regulation to change the Medicare Shared Savings Program (MSSP) so that accountable care organizations (ACOs) take on risk faster creates a one-size-fits-all model that doesn’t allow for variability, said Joe Antos, PhD, the Wilson H. Taylor Resident Scholar in Health Care and Retirement Policy at the American Enterprise Institute.
The proposed CMS regulation to change the Medicare Shared Savings Program (MSSP) so that accountable care organizations (ACOs) take on risk faster creates a one-size-fits-all model that doesn’t allow for variability, said Joe Antos, PhD, the Wilson H. Taylor Resident Scholar in Health Care and Retirement Policy at the American Enterprise Institute.
Transcript
How do you think pushing more accountable care organizations (ACOs) to take on risk faster will impact participation in the MSSP?
I’m concerned about the new CMS regulation, because it’s not at all clear that giving ACOs 5 years, I believe it is, and you’re either successful or you’re out, necessarily makes sense. There’s a lot of variability in healthcare. That’s the problem. And there’s a lot of variability geographically, and a whole bunch of other factors are at work as well.
So, this one-size-fits-all—which, unfortunately, is pretty much the only way the government can set a rule—makes it difficult. I think, in the end, what people have predicted will probably come true, but it might be transitory. I think there will be ACOs who are now in the program who will drop out. There will be some discouragement factor there. Not as many organizations will try to become an ACO, until the kinks are worked out. I think that’s the issue. Because it’s not just “there’s a rule.” It’s, “well, how does CMS actually implement it and are there ways to deal with whatever the hard barriers are?” These are businesses—they’ll find ways.
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
VBID, Heading Into a Third Decade, Looks to Promote Personalization and Access
March 12th 2025Speakers at the 2025 Value-Based Insurance Design summit recapped the accomplishments made over the past 20 years in designing insurance benefits with value in mind and looked ahead to iterations to come.
Read More
Advancing HIV Care With Doravirine and Islatravir: Q&A With Amy Colson, MD, MPH
March 12th 2025New data from the MK-8591A-051 and MK-8591A-052 trials, both investigating the efficacy and safety of 100-mg doravirine and 0.25-mg islatravir as a once-daily 2-drug regimen for virologically suppressed people living with HIV-1, were presented today by Amy Colson, MD, MPH.
Read More